FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283368482> ?p ?o ?g. }

• W4283368482 endingPage "1990" @default.
• W4283368482 startingPage "1989" @default.
• W4283368482 abstract "Background: Patients (pts) with refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes with standard treatment. Loncastuximab tesirine (loncastuximab tesirine-lpyl; Lonca), an antibody-drug conjugate (ADC) comprising a humanized anti-CD19 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer toxin, is approved in R/R DLBCL based on data from the phase 2 LOTIS-2 trial (Caimi et al. Lancet Oncol 2021). Rituximab (R) is part of standard immunochemotherapy for DLBCL, both as frontline therapy and in subsequent treatments. Preclinical evidence suggests that the addition of rituximab to anti-CD19 ADC therapy may result in prolonged tumor control (Ryan et al. Blood 2017). Aims: LOTIS-5 aims to evaluate Lonca-R vs. standard immunochemotherapy of R + gemcitabine + oxaliplatin (R-GemOx) in pts with R/R DLBCL. Methods: This is a phase 3 randomized open-label, two-part, two-arm multicenter study of Lonca-R in pts with R/R DLBCL (NCT04384484). A review of safety data from the nonrandomized safety run-in (Part 1), comparing the safety of Lonca-R to previous Lonca safety data, was completed in January 2022. The trial is now continuing to the randomized phase (Part 2). In Part 2, approximately 330 pts will be randomized 1:1 to receive Lonca-R or R-GemOx. The primary objective of the study is to evaluate the efficacy of Lonca-R versus R-GemOx. The primary endpoint is progression-free survival by independent central review (ICR). Secondary endpoints include overall survival, overall response rate (by ICR using 2014 Lugano classification), complete response rate by ICR, duration of response by ICR, frequency and severity of adverse events, changes from baseline in safety laboratory and clinical variables, concentration and pharmacokinetic parameters of Lonca (conjugated and total antibody and unconjugated warhead), immunogenicity, and changes in patient-reported outcomes. The time to event endpoints will be analyzed based on the intent-to-treat population using a stratified log-rank test. The dosing regimen for Lonca-R: Lonca at 0.15 mg/kg + rituximab at 375 mg/m2 every 3 weeks (Q3W) for 2 cycles and then Lonca at 0.075 mg/kg + rituximab at 375 mg/m2 Q3W for up to 6 cycles. The dose regimen of R-GemOx: rituximab at 375 mg/m2, gemcitabine at 1000 mg/m2, and oxaliplatin at 100 mg/m2 every 2 weeks for up to 8 cycles. Key inclusion criteria include age ≥18 years, pathologic diagnosis of DLBCL (including pts with DLBCL transformed from indolent lymphoma) or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, ≥1 line of prior systemic therapy, not being a candidate for stem cell transplantation, and measurable disease per the 2014 Lugano classification. Results: The randomized part of LOTIS-5 commenced in January 2022, and recruitment is ongoing. Summary/Conclusion: N/A" @default.
• W4283368482 created "2022-06-25" @default.
• W4283368482 creator A5005446862 @default.
• W4283368482 creator A5006164793 @default.
• W4283368482 creator A5010881749 @default.
• W4283368482 creator A5011030256 @default.
• W4283368482 creator A5022008748 @default.
• W4283368482 creator A5026473422 @default.
• W4283368482 creator A5033508968 @default.
• W4283368482 creator A5042459008 @default.
• W4283368482 creator A5045756861 @default.
• W4283368482 creator A5058592020 @default.
• W4283368482 creator A5080556076 @default.
• W4283368482 creator A5082232325 @default.
• W4283368482 date "2022-06-01" @default.
• W4283368482 modified "2023-10-01" @default.
• W4283368482 title "PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)" @default.
• W4283368482 doi "https://doi.org/10.1097/01.hs9.0000851304.16627.3a" @default.
• W4283368482 hasPublicationYear "2022" @default.
• W4283368482 type Work @default.
• W4283368482 citedByCount "0" @default.
• W4283368482 crossrefType "journal-article" @default.
• W4283368482 hasAuthorship W4283368482A5005446862 @default.
• W4283368482 hasAuthorship W4283368482A5006164793 @default.
• W4283368482 hasAuthorship W4283368482A5010881749 @default.
• W4283368482 hasAuthorship W4283368482A5011030256 @default.
• W4283368482 hasAuthorship W4283368482A5022008748 @default.
• W4283368482 hasAuthorship W4283368482A5026473422 @default.
• W4283368482 hasAuthorship W4283368482A5033508968 @default.
• W4283368482 hasAuthorship W4283368482A5042459008 @default.
• W4283368482 hasAuthorship W4283368482A5045756861 @default.
• W4283368482 hasAuthorship W4283368482A5058592020 @default.
• W4283368482 hasAuthorship W4283368482A5080556076 @default.
• W4283368482 hasAuthorship W4283368482A5082232325 @default.
• W4283368482 hasBestOaLocation W42833684821 @default.
• W4283368482 hasConcept C121332964 @default.
• W4283368482 hasConcept C121608353 @default.
• W4283368482 hasConcept C126322002 @default.
• W4283368482 hasConcept C142424586 @default.
• W4283368482 hasConcept C143998085 @default.
• W4283368482 hasConcept C168563851 @default.
• W4283368482 hasConcept C203092338 @default.
• W4283368482 hasConcept C2778559949 @default.
• W4283368482 hasConcept C2779338263 @default.
• W4283368482 hasConcept C2780653079 @default.
• W4283368482 hasConcept C2780962732 @default.
• W4283368482 hasConcept C31760486 @default.
• W4283368482 hasConcept C526805850 @default.
• W4283368482 hasConcept C535046627 @default.
• W4283368482 hasConcept C71924100 @default.
• W4283368482 hasConcept C87355193 @default.
• W4283368482 hasConceptScore W4283368482C121332964 @default.
• W4283368482 hasConceptScore W4283368482C121608353 @default.
• W4283368482 hasConceptScore W4283368482C126322002 @default.
• W4283368482 hasConceptScore W4283368482C142424586 @default.
• W4283368482 hasConceptScore W4283368482C143998085 @default.
• W4283368482 hasConceptScore W4283368482C168563851 @default.
• W4283368482 hasConceptScore W4283368482C203092338 @default.
• W4283368482 hasConceptScore W4283368482C2778559949 @default.
• W4283368482 hasConceptScore W4283368482C2779338263 @default.
• W4283368482 hasConceptScore W4283368482C2780653079 @default.
• W4283368482 hasConceptScore W4283368482C2780962732 @default.
• W4283368482 hasConceptScore W4283368482C31760486 @default.
• W4283368482 hasConceptScore W4283368482C526805850 @default.
• W4283368482 hasConceptScore W4283368482C535046627 @default.
• W4283368482 hasConceptScore W4283368482C71924100 @default.
• W4283368482 hasConceptScore W4283368482C87355193 @default.
• W4283368482 hasLocation W42833684821 @default.
• W4283368482 hasLocation W42833684822 @default.
• W4283368482 hasLocation W42833684823 @default.
• W4283368482 hasLocation W42833684824 @default.
• W4283368482 hasOpenAccess W4283368482 @default.
• W4283368482 hasPrimaryLocation W42833684821 @default.
• W4283368482 hasRelatedWork W1598567296 @default.
• W4283368482 hasRelatedWork W1996279342 @default.
• W4283368482 hasRelatedWork W2020184844 @default.
• W4283368482 hasRelatedWork W2117460825 @default.
• W4283368482 hasRelatedWork W2152161571 @default.
• W4283368482 hasRelatedWork W2344519974 @default.
• W4283368482 hasRelatedWork W2899250601 @default.
• W4283368482 hasRelatedWork W2971092198 @default.
• W4283368482 hasRelatedWork W3031222282 @default.
• W4283368482 hasRelatedWork W3031860663 @default.
• W4283368482 hasVolume "6" @default.
• W4283368482 isParatext "false" @default.
• W4283368482 isRetracted "false" @default.
• W4283368482 workType "article" @default.